CINCINNATI and ANAHEIM, Calif., Nov. 14, 2016 /PRNewswire/ -- Schulman IRB, the industry-leading central IRB in customer service and technology, is pleased to announce its Central Oncology Review (COR) division is open for business.
COR, which is led by Michele Russell-Einhorn, VP of Oncology, and Judith Carrithers, Director of Oncology Services, provides collaborative, flexible IRB review services for oncology research organizations seeking a more advanced level of partnership and service integration from a central IRB. This service represents Schulman's response to requests from institutional research centers. "We are intimately familiar with the unique requirements of cancer research centers and institutional IRBs," said Russell-Einhorn. "COR combines our deep understanding of this environment with Schulman IRB's best-in-class customer service and compliance record, providing cancer research centers and their IRBs with unparalleled transparency and collaboration throughout the review process." In addition to the leadership of Russell-Einhorn and Carrithers, COR features an IRB roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research. COR will assist research organizations in meeting the challenges of regulatory changes like NIH's single IRB policy and HHS' proposed changes to the "Common Rule," which will require multicenter research studies to be overseen by a central IRB.